report
volunt
rapporteur
provid
summari
scientif
present
hope
effect
convey
speaker
goal
result
conclus
talk
report
provid
overview
invit
keynot
award
lectur
highlight
short
oral
present
perspect
expert
antivir
research
note
session
human
cytomegaloviru
includ
updat
introduct
clinic
letermovir
prevent
cmv
infect
diseas
st
icar
success
promot
new
discoveri
antivir
research
drug
develop
intern
societi
antivir
research
isar
sponsor
annual
intern
meet
intern
confer
antivir
research
icar
st
icar
held
confer
center
porto
portug
june
previou
year
andrei
et
al
vere
hodg
meet
provid
interdisciplinari
forum
investig
involv
basic
translat
clinic
research
worldwid
met
review
recent
develop
area
antivir
research
drug
vaccin
develop
overarch
goal
confer
drive
discoveri
new
antivir
therapi
foster
collabor
among
scientist
field
basic
virolog
medicin
chemistri
pharmacolog
anim
model
diseas
toxicolog
academia
pharmaceut
industri
honor
scientist
receiv
isar
award
excel
elion
award
lectur
provid
perfect
set
discuss
recent
advanc
anticmv
treatment
women
scienc
wi
award
lectur
remind
us
urgent
need
understand
effect
combat
viru
transmiss
neglect
popul
intric
world
hostpathogen
interact
antivir
drug
suscept
highlight
prusoff
lectur
award
lectur
recogn
synthesi
prodrug
hot
topic
field
medicin
chemistri
biolog
scienc
revolution
big
data
new
genom
sequenc
imag
technolog
antivir
field
except
revolut
nextgener
sequenc
chang
way
recogn
diagnos
emerg
drug
resist
prevent
treatment
failur
genom
proteom
help
identif
host
factor
new
target
drug
develop
cryoelectron
microscopi
cryoem
tomographi
offer
unpreced
highresolut
imag
viru
particl
year
icar
recogn
need
discuss
revolut
special
session
recent
technolog
advanc
mutagenesi
human
genom
may
use
deciph
viru
entri
excel
introductori
lectur
cryoelectron
microscopi
imag
reconstruct
among
highlight
year
confer
similarli
new
expertis
may
appli
understand
predict
evolut
viru
infect
recogn
role
new
strategi
address
longstand
unresolv
question
http
receiv
juli
accept
august
winner
year
elion
award
paul
griffith
whose
award
lectur
focus
develop
vaccin
prevent
human
cytomegaloviru
hcmv
infect
infant
congenit
receiv
stem
cell
solid
organ
transplant
transplant
solid
organ
provis
organ
hcmvposit
donor
hcmvneg
recipi
r
result
greatest
chanc
diseas
viral
load
certain
titer
greatest
predictor
threshold
concept
paul
present
idea
viral
peak
shiftif
vaccin
shift
time
peak
viral
titer
occur
shift
onset
diseas
thu
allow
time
antivir
therapi
treat
viru
turn
problemat
sometim
fatal
diseas
vaccin
appear
induc
tand
bcell
respons
introduct
deplet
immun
still
effect
studi
date
vaccin
rpatient
result
decreas
incid
reinfect
mechan
action
antibodi
produc
result
vaccin
still
investig
could
antibodi
caus
viru
neutral
lysi
infect
cell
prior
shed
paul
final
thought
revolv
around
develop
antihcmv
drug
antivir
still
necessari
next
year
upon
introduct
vaccin
mass
vaccin
popul
lectur
chri
meier
nice
review
effort
team
design
synthes
prodrug
nucleosid
monophosph
nmp
diphosph
ndp
triphosph
ntp
meier
use
prodrug
deliveri
nucleotidebas
antivir
hot
topic
field
medicin
chemistri
reason
mask
nucleotid
clear
bypass
phosphoryl
step
due
limit
metabol
nucleosid
analogu
cell
effici
deliveri
polar
nucleotid
analogu
cell
chri
first
summar
develop
cyclosalapproach
intracellular
deliveri
nmp
fig
salicyl
alcohol
use
cyclic
bifunct
mask
group
releas
parent
nmp
chemic
driven
meier
balzarini
also
numer
type
nmp
prodrug
success
protid
technolog
pioneer
chri
mcguigan
cardiff
uk
current
use
improv
drug
deliveri
eg
tenofovir
alafenamid
sofosbuvir
mehel
et
al
slusarczyk
et
al
ntp
usual
antivir
activ
speci
direct
deliveri
ntp
ndp
would
benefici
chemic
also
quit
challeng
direct
deliveri
triphosph
diphosph
form
nucleosid
analogu
would
desir
impract
instabl
synthesi
tan
et
al
especi
challeng
chemistri
viewpoint
design
ndp
ntp
prodrug
specif
select
remov
three
four
mask
group
respect
next
phosphat
anhydrid
bond
achiev
expect
nucleophil
eg
intracellular
water
would
attack
phosphoru
atom
lead
cleavag
anhydrid
bond
fulli
mask
ndp
ntp
key
idea
chri
approach
avoid
undesir
cleavag
keep
neg
charg
ndp
ntp
moieti
nucleophil
would
attack
posit
due
electrostat
repuls
would
lead
increas
chemic
stabil
phosphat
anhydrid
bond
prodrug
ndp
ntp
prodrug
chri
next
report
dipproapproach
fig
develop
deliveri
ndp
cell
bypass
second
phosphoryl
step
meier
especi
mention
nonsymmetr
dipproapproach
control
stepwis
remov
prodrug
moieti
led
highli
select
deliveri
ndp
weinschenk
et
al
ultim
challeng
design
synthesi
ntp
prodrug
socal
trippproapproach
fig
two
differ
routesphosphoramidit
hphosphon
chemistrieswer
use
synthesi
target
trippprocompound
good
yield
dipproapproach
trippprocompound
bear
two
lipophil
group
termin
phosphat
moieti
gollnest
et
al
gollnest
et
al
one
easili
play
mask
group
order
tune
lipophil
stabil
prodrug
molecul
longer
alkyl
chain
increas
lipophil
molecul
compens
neg
charg
moieti
also
enhanc
stabil
enzymat
hydrolysi
trippprocompound
use
porcin
liver
esteras
ple
show
select
format
ntp
fig
format
triphosph
furthermor
proven
primerextens
assay
final
chri
demonstr
sever
exampl
trippprocompound
deriv
wellknown
antivir
agent
ddc
zalcitabin
stavudin
abacavir
sofosbuvir
exampl
stavudin
triphosph
prodrug
shown
releas
activ
metabolit
exhibit
good
antihiv
activ
tkdefici
cell
studi
mice
applic
trippproderiv
base
sofosbuvir
nucleosid
led
twofold
increas
concentr
correspond
triphosph
liver
compar
sofosbuvir
women
scienc
award
desire
labeaud
pediatr
infecti
diseas
stanford
univers
stanford
ca
usa
year
women
scienc
awarde
desire
labeaud
began
talk
describ
breadth
attribut
dengu
viral
denv
chikungunya
chikv
infect
larg
impact
neglect
popul
note
vectorborn
diseas
estim
account
infecti
diseas
one
million
death
per
year
spread
larg
due
influenc
modern
life
includ
signific
travel
billion
peopl
year
increas
nich
lead
mosquito
breed
diseas
endem
epidem
million
case
dengu
per
year
africa
year
kenya
experienc
outbreak
chikv
kenya
alon
children
expos
denv
chikv
though
develop
diseas
desire
note
tremend
need
antivir
vaccin
treat
prevent
dengu
chikungunya
diseas
well
continu
effort
increas
awar
reduc
breed
ground
mosquito
desire
present
find
infect
diseas
denv
chikv
four
urban
rural
site
kenya
studi
includ
two
cohort
children
first
compris
acut
ill
children
year
old
recruit
per
site
per
week
seen
ill
onset
one
month
later
also
posit
malaria
second
cohort
contain
approxim
healthi
children
age
year
studi
site
visit
everi
month
sinc
incept
studi
case
fever
due
denv
infect
due
chikv
infect
stabl
sourc
viru
commun
outsid
outbreak
incid
diseas
equal
across
age
howev
outbreak
incid
diseas
increas
increas
age
probabl
due
human
movement
note
diseas
longterm
effect
note
dengu
patient
fulli
recov
month
postinfect
fare
wors
malaria
coinfect
vu
et
al
conclus
talk
desire
describ
work
mosquito
popul
reduct
strategi
reduc
diseas
specif
note
number
contain
purpos
left
commun
fill
stagnant
water
drove
breed
mosquito
began
program
involv
children
mother
collect
burial
contain
well
ad
lid
use
water
contain
intervent
strategi
major
impact
reduc
mosquito
popul
variou
activ
initi
introduc
commun
includ
game
children
collect
unus
contain
ester
ballana
began
lectur
introduc
role
host
factor
modul
viru
infect
particular
restrict
factor
host
antivir
protein
counteract
restrict
viral
replic
consid
first
line
defens
virus
incom
pathogen
sterilealphamotifandhistidineaspartatedomaincontain
protein
member
uniqu
group
restrict
factor
limit
retrovir
replic
distinct
stage
viral
life
cycl
ballana
est
vpx
induc
degrad
target
proteasom
addit
ubiquitin
ub
bypass
viral
restrict
tightli
link
cellintrins
innat
immun
respons
direct
antivir
defens
trigger
interferon
ifn
product
regul
cell
cycl
cell
prolifer
fig
phosphoryl
cyclindepend
kinas
cdk
associ
deactiv
restrict
activ
replic
primari
lymphoid
myeloid
cell
badia
et
al
select
inhibitor
imped
phosphoryl
activ
function
block
replic
paul
et
al
restrict
infect
revers
transcriptas
step
nonprolifer
cell
put
restrict
mechan
lie
dntptriphosphohydrolas
activ
regul
intracellular
dntp
pool
ester
show
modul
nucleotid
analogu
efficaci
wherea
sensit
nonnucleosid
inhibitor
nevirapin
nucleosid
phosphon
cidofovir
tenofovir
affect
howev
also
show
could
either
enhanc
reduc
antivir
potenc
anticanc
analogu
effect
depend
specif
nucleotid
target
capac
act
substrat
competitor
catalyt
site
natur
nucleotid
addit
select
cdk
inhibitor
also
modifi
antivir
activ
antimetabolit
activ
lost
cell
conclud
modul
function
may
constitut
promis
target
improv
multipl
therapi
employ
nucleotid
analogu
antimetabolit
affect
dntp
pool
neurodevelopment
sequela
congenit
cmv
infect
role
virusiinduc
inflamm
william
britt
depart
pediatr
microbiolog
neurobiolog
school
medicin
univers
alabama
birmingham
alabama
usa
bill
britt
present
inform
congenit
hcmv
infect
whose
longterm
sequela
primarili
associ
damag
central
nervou
system
damag
mechan
injuri
remain
undefin
still
understood
much
damag
infant
low
level
viru
recent
studi
use
anim
model
autopsi
patient
indic
host
inflammatori
respons
play
pivot
role
develop
diseas
specif
auditori
defici
use
murin
cytomegaloviru
mcmv
model
defin
mechan
cn
diseas
bill
studi
demonstr
host
inflammatori
respons
respons
alter
neurodevelop
infect
mice
cn
develop
stage
block
inflamm
prednisolon
antitnf
antibodi
decreas
incid
even
though
major
chang
viru
replicationtit
data
indic
antivir
therapi
antiinflammatori
agent
could
improv
longterm
outcom
infant
congenit
hcmv
infect
david
kimberlin
present
inform
infant
symptomat
cmv
infect
straightforward
diagnos
sinc
clinic
manifest
drive
diagnosi
asymptomat
infect
diagnosi
difficult
achiev
though
broadbas
screen
hcmvinduc
hear
loss
may
present
birth
develop
year
age
delay
onset
data
avail
infant
symptomat
diseas
treatment
start
first
month
follow
diagnosi
longcours
ganciclovir
gcv
treatment
result
reduct
worseningabnorm
hear
loss
month
therapi
superior
week
main
advers
effect
neutropenia
lessen
use
valganciclovir
compar
iv
gcv
addit
drug
treatment
hcmv
develop
use
monotherapi
combin
valganciclovir
treatment
congenit
hcmv
appear
promis
letermovir
current
state
art
randi
leavitt
clinic
research
msd
north
wale
pa
usa
randi
leavitt
present
data
letermovir
let
prophylaxi
phase
trial
haematopoiet
stem
cell
transplant
hsct
recipi
marti
et
al
preemptiv
therapi
initi
viremia
detect
associ
increas
risk
overal
mortal
prophylact
therapi
therefor
prefer
result
use
let
demonstr
decreas
therapi
failur
primarili
due
clinic
signific
level
hcmv
addit
week
decreas
time
infect
let
vs
placebo
final
signific
decreas
advers
event
compar
placebo
neutropenia
observ
safer
efficaci
prophylact
agent
prevent
hcmv
infect
import
public
health
research
util
let
current
way
letermovir
resist
analysi
clinic
trial
cytomegaloviru
prophylaxi
haematopoiet
cell
transplant
recipi
cameron
dougla
infecti
diseas
research
merck
co
inc
kenilworth
nj
usa
cameron
dougla
provid
inform
let
resist
clinic
trial
hcmv
prophylaxi
hsct
recipi
cmv
common
potenti
lifethreaten
viral
infect
patient
popul
cmv
r
undergo
hsct
high
risk
cmv
reactiv
cmv
infect
associ
increas
mortal
let
hcmv
dna
terminas
inhibitor
ec
valu
clinic
isol
rang
nm
let
activ
strain
mutat
confer
resist
dna
polymeras
inhibitor
base
posit
result
phase
clinic
trial
hcmv
prophylaxi
hsct
recipi
marti
et
al
let
approv
eu
prophylaxi
cmv
reactiv
diseas
adult
cmv
r
allogen
hsct
recommend
dosag
mg
daili
initi
earli
day
day
posttransplant
continu
day
dose
decreas
mg
daili
administ
cyclosporin
cameron
present
analysi
let
resist
phase
trial
subject
experienc
clinic
signific
cmv
infect
cscmvi
detect
dnaemia
present
total
dna
isol
plasma
time
cscmvi
cmv
gene
encod
subunit
terminas
complex
amplifi
pcr
nextgener
sequenc
perform
genotyp
success
carri
let
subject
cscmvi
includ
subject
fig
link
cell
cycl
suscept
primari
cell
regul
intracellular
dntp
essenti
normal
cellular
metabol
balanc
suppli
four
canon
dntp
requir
accur
genom
mitochondri
dna
synthesi
repair
nucleotid
metabol
therefor
precis
regul
differ
stage
cell
cycl
activ
depend
cell
cycl
regul
cyclindepend
kinas
cdk
phosphoryl
lead
inactiv
turn
natur
cdk
inhibitor
promot
activ
revers
transcriptas
activ
favor
inact
high
dntp
level
figur
detect
cmv
dna
day
prophylaxi
replic
test
perform
identifi
novel
genotyp
chang
pcr
artifact
rather
true
variant
number
previous
character
natur
genet
polymorph
impact
let
suscept
also
seen
remain
novel
variant
character
potenti
confer
resist
recombin
phenotyp
use
bac
system
identifi
three
variant
confer
let
ec
shift
cellcultur
model
infect
mutat
three
subject
receiv
let
experienc
cscmvi
mutat
associ
modest
let
ec
shift
detect
ng
read
subject
cmv
dna
copiesml
interestingli
subject
placebo
arm
also
substitut
low
frequenc
ng
read
mutant
let
shift
detect
subject
miss
first
dose
let
amino
acid
substitut
also
detect
subject
enrol
phase
trial
receiv
suboptim
mg
let
dose
mutant
let
shift
patient
cmv
dnaemic
day
notabl
recombin
virus
bear
substitut
show
littl
chang
suscept
ganciclovir
cidofovir
foscarnet
phase
trial
conduct
inform
letresist
mutat
gene
analyz
fit
studi
terminasemut
virus
show
major
growth
impair
session
recent
technolog
advanc
present
two
novel
robust
experiment
approach
use
better
understand
viral
replic
appli
tool
antivir
drug
discoveri
mutagenesi
human
genom
studi
viru
entri
thijn
brummelkamp
netherland
cancer
institut
dept
biochemistri
amsterdam
netherland
thijn
brummelkamp
describ
use
haploid
human
cell
combin
insert
mutagenesi
robust
potent
tool
identifi
host
factor
use
virus
began
describ
approach
base
deriv
chronic
myeloid
leukemia
cml
cell
line
haploid
karyotyp
use
genetrap
retrovirus
contain
green
fluoresc
protein
gfp
marker
revers
orient
retrovir
backbon
describ
gene
inactiv
insert
mutagenesi
allow
gener
null
mutant
nonessenti
gene
cell
line
genetrap
insert
map
deep
sequenc
group
appli
approach
identifi
host
factor
use
virus
differ
famili
present
sever
exampl
illustr
power
haploid
genet
screen
thijn
first
describ
identif
endolysosom
cholesterol
transport
protein
niemannpick
host
factor
requir
ebola
viru
entri
carett
et
al
studi
provid
mechanist
evid
ebola
glycoprotein
directli
bind
insid
cell
miller
et
al
present
similar
result
lassa
viru
lysosomeassoci
membran
protein
show
virus
need
cellular
trigger
permit
bind
viral
envelop
protein
intracellular
receptor
appli
technolog
picornavirida
two
distinct
factor
identifi
thijn
show
cell
surfac
molecul
identifi
major
entri
receptor
coxsacki
viru
requir
pathogenesi
stare
et
al
addit
phospholipas
also
recogn
picornaviru
host
factor
requir
earli
infect
enabl
virionmedi
genom
deliveri
cytoplasm
remark
absenc
incom
virion
subject
antibacteri
clearanc
pathway
stare
et
al
sarah
butcher
began
provid
detail
descript
basi
electron
cryoem
techniqu
signific
improv
imag
reconstruct
technolog
improv
number
qualiti
highresolut
structur
recent
year
describ
pipelin
cryoem
technolog
base
vitrif
sampl
aqueou
solut
follow
rapid
immers
liquid
ethan
final
imag
frozenhydr
sampl
special
transmiss
electron
microscop
explain
imag
record
process
gener
averag
threedimension
represent
model
atom
coordin
object
elimin
need
crystal
second
part
sarah
talk
focus
applic
cryoem
drug
discoveri
gave
two
exampl
first
describ
use
cryoem
guid
design
benzenesulfonamid
deriv
antivir
drug
coxsacki
b
viru
case
atom
analysi
viral
capsid
protein
bound
drug
allow
identif
new
hydrophob
drugbind
pocket
data
resist
mutat
map
bind
pocket
reveal
cryoem
suggest
newli
reveal
structur
could
potenti
target
develop
novel
inhibitor
next
use
respiratori
syncyti
viru
rsv
exampl
structur
heterogen
among
viral
particl
electron
cryotomograph
character
rsv
virion
show
highli
heterogen
architectur
either
spheric
filament
combin
morpholog
cryoem
follow
subtomogram
averag
reveal
differ
morpholog
correl
local
order
glycoprotein
spike
either
prefus
postfus
conform
liljeroo
et
al
sum
sarah
discuss
advantag
caveat
cryoem
technolog
highlight
enorm
potenti
especi
resolv
structur
small
protein
mda
also
point
still
unresolv
issu
averag
comput
requir
need
develop
standard
valid
method
keynot
address
hepat
c
viru
problem
solv
jeanmichel
pawlotski
univers
parisest
pari
franc
jeanmichel
pawlotski
told
revolutionari
stori
antihepat
c
viru
hcv
drug
develop
cover
relev
aspect
includ
hcv
medic
burden
mileston
direct
act
antivir
daa
discoveri
combin
paradigm
handl
drug
resist
current
standard
care
industri
countri
forget
state
huge
effort
still
need
identifi
hcv
patient
particularli
lowincom
countri
treat
potenti
elimin
diseas
worldwid
current
far
achiev
goal
chronic
hcv
infect
lethal
diseas
long
term
lead
hepatocellular
carcinoma
hcc
undiagnos
untreat
patient
first
line
therapi
base
nonspecif
interferonalpha
initi
free
pegyl
combin
ribavirin
associ
poor
sustain
virolog
respons
svr
hcv
encod
sever
enzym
target
protein
includ
serin
proteas
polyfunct
protein
polymeras
therefor
drug
target
viral
function
soon
develop
test
clinic
jeanmichel
remind
us
path
without
difficulti
mani
earli
drug
eg
boceprevir
telaprevir
fail
late
stage
clinic
evalu
approv
quickli
replac
better
drug
major
mileston
approv
sofosbuvir
potent
nucleotid
analogu
target
drug
remain
backbon
combin
therapi
year
mani
potent
drug
target
either
approv
combin
bi
tritherapi
reach
virtual
svr
patient
pangenotyp
manner
fig
patient
benefit
treatment
lead
cure
earlier
treat
greater
reduct
risk
develop
complic
decompens
cirrhosi
hcc
world
health
organ
goal
new
infect
prevent
elig
patient
treat
reduct
mortal
rate
countri
australia
egypt
england
franc
germani
japan
spain
other
track
road
map
mani
other
need
improv
nation
action
plan
far
estim
around
patient
treat
worldwid
china
count
million
infect
peopl
diagnos
treat
www
polarisobservatoryorg
know
let
make
happen
perci
knoll
gave
excel
stateoftheart
lectur
mechan
immun
disfunct
chronic
hepat
b
possibl
immun
therapi
chronic
hbv
infect
affect
million
individu
worldwid
exist
prophylact
vaccin
useless
cur
treatment
option
exist
inde
current
sole
therapeut
option
reli
either
nucleosid
analogu
option
lead
hbsag
loss
call
function
cure
patient
contrast
hepat
c
cure
directact
antivir
expect
immunotherapi
sort
necessari
function
cure
chronic
hbv
infect
first
perci
remind
us
hbv
infect
occur
context
physiolog
tolerogen
environ
liver
ie
high
level
arginas
product
liver
macrophag
myeloid
cell
lsec
hepatocyt
may
initi
favor
viral
replic
absenc
primari
innat
cellmedi
inflamm
render
possibl
induct
tcell
exhaustionattrit
patient
around
immunocompet
adult
virolog
context
high
persist
replic
chronic
infect
patient
longlast
failur
hbvspecif
immun
respons
result
persist
yet
mani
patient
hbv
infect
remain
acut
clear
rapidli
strong
polyepitop
tcell
respons
impli
infect
defeat
immun
respons
chronic
infect
patient
one
would
break
hbvdriven
immun
subvers
restor
full
control
viru
therapeut
vaccin
strategi
fail
restor
immun
control
infect
list
past
current
trial
see
tabl
rest
present
perci
focus
effort
develop
therapeut
vaccin
option
base
protein
prime
mvavector
boost
strategi
patient
alreadi
receiv
nucleosid
analogu
nuc
nuc
therapi
reduc
viremia
therefor
therapeut
vaccin
occur
context
low
serum
viru
titer
thervacb
strategi
develop
prof
ulrik
protzer
institut
virolog
munich
reli
first
protein
prime
hbv
surfac
antigen
core
protein
induc
neutral
antibodi
prime
cell
boost
mva
vector
encod
variou
hbv
epitop
disclos
given
expand
hbvspecif
cell
liver
parenchym
secondarytertiari
lymphoid
structur
call
imat
huang
et
al
demonstr
efficaci
approach
perci
use
immunecompet
mous
model
transduc
adenovirusassoci
viru
vector
carri
hbv
genom
aavhbv
dion
et
al
aavhbv
launch
persist
infect
mice
recapitul
tcell
exhaust
phenotyp
model
thervacb
induc
hbsag
loss
antihb
antibodi
product
antihb
seroconvers
effector
hbsspecif
intrahepat
cell
imat
interestingli
format
imat
also
favor
adjuvant
procedur
base
cpg
agonist
ligand
subcellular
level
indepth
mechanist
effort
perci
present
unpublish
data
show
imat
induc
signal
pathway
lead
rosmedi
mitochondria
reshap
preclin
valid
thervacb
strategi
need
clinic
evalu
patent
approach
soon
david
durantel
lectur
summar
current
effort
develop
molecul
target
assembl
hbv
nucleocapsid
therebi
prevent
neosynthesi
viral
dna
core
hbc
structur
protein
assembl
capsid
around
pregenom
rna
revers
transcript
take
place
gener
relax
circular
dna
rcdna
core
assembl
modul
cam
inhibit
process
neosynthesi
rcdna
similar
action
nucleosid
analogu
nuc
hbc
protein
also
regulatori
function
infect
cell
david
remind
us
cell
high
level
hbv
replic
hbc
nucleu
bind
cccdna
may
contribut
transcript
activ
stabil
hbc
also
bind
host
dna
may
regul
host
gene
express
final
hbc
mainli
rnabind
protein
could
bind
viral
rna
regul
fate
due
multifunct
charact
hbc
cam
might
initi
envisag
two
main
class
cam
induc
format
empti
aberr
capsid
vitro
fig
class
sever
scaffold
chemotyp
describ
cell
cultur
model
effici
inhibit
product
virion
progeni
ec
nanomolar
rang
therapeut
indic
high
cam
also
inhibit
secret
rnacontain
particl
genomefre
particl
nuc
import
mani
hbccontain
particl
circul
blood
patient
function
yet
fulli
understood
david
also
report
secondari
mode
action
cam
effici
concentr
ec
inhibit
format
cccdna
administ
viru
anim
model
berk
et
al
cam
inhibit
accumul
intracellular
vrna
prevent
hbeag
secret
hbeag
produc
larg
excess
blood
patient
immunesubvers
properti
seroconvers
antihbeag
statu
import
clinic
therapeut
endpoint
cam
could
acceler
process
david
indic
cam
combin
nuc
pegifn
combin
test
preclin
anim
model
hbv
infect
synergist
would
desir
obtain
human
final
present
result
phase
clinic
trial
tabl
gener
cam
lead
rapid
declin
viremia
ie
reduct
day
treatment
sever
advers
effect
report
trial
result
avail
earli
result
interest
longterm
safeti
cam
superior
cam
nuc
yet
proven
one
remain
cautiou
wait
result
phase
trial
eva
riveiramunoz
irsicaixa
aid
research
institut
barcelona
spain
report
interest
result
regard
potenti
antihiv
activ
known
antimetabolit
strategi
inhibit
target
phosphoryl
via
dntpase
activ
mediat
activ
reduc
pool
dntp
also
modul
activ
antimetabolit
pemetrex
pmtx
basal
antihiv
anticanc
activ
dntpase
activ
inactiv
phosphoryl
inhibit
phosphoryl
could
therefor
lead
pronounc
antihiv
activ
due
dntp
depriv
studi
elegantli
show
involv
phosphoryl
inhibit
palbociblib
pb
prevent
phosphoryl
turn
potenti
antihiv
activ
pmtx
inde
combin
pb
pmtx
increas
effect
replic
well
increas
anti
cancer
effect
combin
index
ci
combin
could
prove
use
therapeut
strategi
maria
pujantel
also
irsicaixa
aid
research
institut
barcelona
show
experiment
evid
atoi
edit
cellular
adenosin
deaminas
act
rna
function
regul
innat
antivir
immun
function
hcv
infect
report
key
step
trigger
innat
immun
respons
foreign
viral
rna
includ
knockdown
enhanc
express
rna
sensor
rigi
phosphoryl
express
phosphoryl
indic
innat
immun
activ
polymorph
within
gene
found
significantli
associ
clinic
respons
interferon
therapi
advanc
liver
fibrosi
cohort
hcvand
coinfect
patient
pujantel
et
al
conclud
regul
innat
immun
signal
import
contributor
outcom
hcvhost
interact
bingqian
qu
depart
infecti
diseas
univers
heidelberg
germani
present
data
antihbv
activ
activ
enzym
nae
inhibitor
pevonedistat
antihepat
delta
viru
activ
report
previous
describ
antitumor
drug
lan
et
al
neddyl
import
process
activ
cullinringligas
crl
largest
famili
ubiquitin
ligas
ubiquitin
cellular
protein
recent
shown
hbv
via
hbx
protein
coopt
crl
ubiquitin
degrad
import
hbv
restrict
factor
et
al
rational
antivir
strategi
inhibit
nae
would
turn
inhibit
crl
therebi
stabil
relev
cell
cultur
infecti
model
inhibit
product
hbv
virion
ec
low
nm
absenc
toxic
nondivid
cell
cccdna
level
unchang
inhibitori
phenotyp
includ
less
accumul
intracellular
viral
rna
remain
determin
whether
reduc
intracellular
vrna
due
defect
transcript
posttranscript
effect
depth
mechanist
studi
await
clarifi
point
vivo
experi
also
plan
valid
approach
preclin
model
tiffani
edward
saint
loui
univers
mo
usa
report
develop
hbv
rnaseh
inhibitor
belong
either
nhydroxyisoquinolinedion
hid
nhydroxypyridinedion
hpd
famili
work
follow
publish
effort
team
improv
efficaci
character
antirnas
activ
compound
vitro
edward
et
al
lomonosova
et
al
recal
rnase
activ
hbv
polymeras
crucial
revers
transcript
pregenom
rna
rcdna
within
nucleocapsid
effort
john
tavi
team
inhibitor
hbv
rnase
describ
ec
hid
hpd
measur
replic
hbv
rang
rather
low
therapeut
indic
higher
author
undertook
structureact
relationship
sar
studi
improv
compound
report
inhibitor
higher
activ
ec
around
nm
greater
therapeut
index
interestingli
synergi
one
best
modal
nucleosid
analogu
ie
lamivudin
also
report
thu
point
toward
combin
possibl
yet
best
hbv
rnase
inhibitor
need
test
relev
vitro
infecti
model
eg
phh
well
preclin
mous
model
hittolead
optim
ongo
melissann
de
wispelaer
harvard
medic
school
usa
present
data
develop
bifunct
molecul
specif
bind
target
viral
protein
induc
degrad
ubiquitin
cullinr
ligas
clr
complex
cromm
crew
first
step
identifi
small
molecul
bind
specif
viral
target
link
anoth
moieti
abl
bind
adapt
clr
fig
exemplifi
strategi
melissann
present
data
induc
degrad
hcv
serin
proteas
two
bifunct
molecul
whose
antivir
potenc
lower
parent
proteas
inhibitor
telaprevir
demonstr
small
molecul
recruit
clr
complex
mediat
degrad
cereblonbind
moieti
modifi
produc
recruit
cereblon
consequ
mediat
degrad
degrad
could
also
prevent
competit
lenalidomid
cereblon
ligand
togeth
experi
demonstr
small
molecul
recruit
clr
complex
mediat
degrad
therebi
inhibit
hcv
jinhong
chang
baruch
blumberg
institut
doylestown
pa
usa
describ
novel
benzamid
compound
modul
hbv
nucleocapsid
assembl
distinct
manner
compar
capsid
assembl
modul
cam
current
develop
antihbv
clinic
start
chemic
bank
around
molecul
use
homemad
screen
assay
base
cell
line
identifi
novel
chemotyp
newli
identifi
chemotyp
also
induc
format
empti
capsid
latter
differ
mobil
optim
ie
slow
run
agaros
capsid
migrat
assay
amongst
molecul
identifi
studi
show
ec
rang
wt
hbv
remain
activ
mutant
ineffect
mutant
similar
cam
indirect
evid
bind
hap
pocket
could
induc
differ
conform
chang
surfac
alter
charg
sar
studi
yet
done
hit
leader
strategi
identifi
drug
candid
viru
evolut
get
root
epidem
spread
evolutionari
perspect
pathogen
emerg
philipp
lemey
depart
microbiolog
immunolog
rega
institut
ku
leuven
belgium
philipp
lemey
present
three
exampl
viral
molecular
epidemiolog
describ
evolut
hiv
ebola
lassa
fever
virus
visual
impress
keynot
present
explain
sequenc
viral
genom
sometim
use
lab
suitcas
portabl
devic
provid
phylodynam
phylogeograph
inform
epidem
bayesian
evolutionari
analysi
sampl
tree
beast
softwar
http
beastcommun
suchard
et
al
employ
reconstruct
epidem
mutat
map
rate
hiv
evolut
calcul
introduct
human
popul
trace
back
kinshasa
democrat
republ
congo
former
belgian
congo
faria
et
al
evid
spread
along
transport
network
indic
path
kinshasa
haiti
new
york
citi
san
francisco
work
also
refut
popular
idea
singl
patient
zero
worobey
et
al
second
exampl
west
african
ebola
epidem
genom
anatomi
determin
sequenc
case
phylogeograph
gener
linear
model
determin
predictor
outbreak
order
import
origin
popul
size
destin
popul
size
geograph
distanc
withincountri
migrat
sharedbord
migrat
duda
et
al
conclud
larg
epidem
consist
heterogen
spatial
dissoci
collect
transmiss
cluster
vari
size
durat
connect
third
exampl
lassa
fever
outbreak
nigeria
still
continu
today
philipp
address
question
whether
increas
case
due
new
viru
strain
could
greater
potenti
humantohuman
transmiss
appli
phylogenet
reconstruct
diverg
date
lassa
viru
genom
obtain
collabor
use
infield
metagenom
approach
increas
incid
human
case
could
attribut
independ
spillov
multimamm
rat
rather
humantohuman
transmiss
welcom
news
public
health
offici
nigeria
summari
philipp
observ
realtim
epidemiolog
surveil
viral
genom
contribut
contain
zoonos
epidem
marco
vignuzzi
present
comput
experiment
tool
studi
rna
viru
evolut
use
compel
graphic
clear
analog
anim
featur
demonstr
research
group
monitor
predict
experiment
alter
rna
viru
evolut
high
mutat
frequenc
rnadepend
rna
polymeras
rdrp
small
genom
make
rna
virus
good
system
studi
sinc
larg
viru
popul
creat
mutant
spectra
cloud
possibl
mutat
sequenc
space
almost
infinit
larg
approach
genom
marco
group
interest
map
fit
landscap
identifi
good
neighborhood
highli
fit
potenti
pathogen
genotyp
occur
repres
fit
peak
landscap
valley
repres
area
deleteri
mutat
loss
virul
experi
begin
pass
viru
coxsacki
b
viru
exampl
five
time
presenc
mutagen
ribavirin
amilorid
mn
result
variant
everi
posit
mutant
swarm
ensu
evalu
nextgener
sequenc
ng
dimens
data
set
reduc
multidimension
scale
tool
pca
captur
biolog
differ
strain
separ
mutat
cluster
minor
chang
spars
pca
identifi
main
contributor
determin
mutat
drive
biolog
signal
submatrix
select
singular
valu
decomposit
smssvd
detect
overlaid
signal
particularli
low
signal
nois
ratio
nonlinear
dimens
reduct
isomap
isomap
best
visual
evolutionari
trajectori
even
replic
viru
strain
analysi
reveal
biolog
signal
could
captur
less
dimens
plot
show
fit
landscap
popul
conclus
minor
variant
critic
determin
fit
phenotyp
identifi
bad
neighborhood
sequenc
space
gener
strain
attenu
vivo
rais
possibl
use
approach
make
vaccin
approach
tool
describ
present
explain
outstand
web
page
vignuzzilabeu
clear
languag
nonexpert
nicki
hwang
baruch
blumberg
institut
inform
audienc
progress
develop
compound
deriv
imino
sugar
deoxynojirimycin
dnj
endoplasm
reticulum
ii
inhibitor
effici
block
replic
sever
hemorrhag
fever
virus
denv
ebola
rift
valley
fever
viru
suffer
short
plasma
halflif
low
oral
bioavail
chang
et
al
four
free
hydroxyl
group
dnj
moieti
use
make
ester
order
overcom
problem
fulli
tetraacyl
partial
diacyl
monoacyl
protect
analogu
prepar
prodrug
retain
antivir
activ
denv
zikv
yellow
fever
ebola
viru
cellbas
assay
demonstr
effici
releas
parent
compound
insid
cell
absorpt
et
al
pharmacokinet
studi
mice
demonstr
prodrug
approach
could
lead
improv
oral
bioavail
efficaci
studi
ebolainfect
mice
show
improv
protect
target
hbv
core
protein
cp
repres
attract
novel
approach
toward
cur
therapi
zhengqiang
wang
univers
minnesota
minneapoli
mn
usa
present
novel
chemotyp
capsid
assembl
effector
cae
origin
hit
identifi
highthroughput
screen
commerci
librari
subsequ
extens
medicin
chemistri
effort
involv
sar
spr
studi
adm
pk
led
discoveri
compound
bind
tightli
cp
potent
inhibit
hbv
replic
nanomolar
rang
ec
ec
respect
compound
improv
oral
bioavail
f
respect
without
observ
cytotox
cc
roberto
manganaro
cardiff
univers
uk
consid
mimick
heptad
repeat
b
hrb
region
respiratori
syncyti
viru
f
protein
potenti
antivir
strategysynthet
peptid
helic
structur
hrb
region
f
protein
earlier
report
potent
inhibitor
rsv
fusion
lambert
et
al
hrb
fdasisqvn
fragment
select
suitabl
templat
ration
design
mimic
sever
chemoinformat
techniqu
use
gener
evalu
focus
virtual
librari
compound
design
mimic
hydrophob
interact
select
hrb
fragment
promis
compound
synthes
evalu
activ
rsvb
cpebas
assay
cell
compound
weakli
activ
rsv
strain
new
analogu
therefor
synthes
order
increas
antivir
activ
birgit
zonsic
also
cardiff
univers
report
discoveri
novel
smallmolecul
inhibitor
chikv
viral
genom
encod
four
nonstructur
protein
macro
domain
known
adpribos
bind
modul
select
target
identif
novel
inhibitor
pharmacophor
screen
fig
develop
bifunct
molecul
specif
bind
target
viral
protein
induc
degrad
small
molecul
ligand
specif
viral
target
conjug
ligand
cereblon
crbn
adapt
cullinringligas
clr
complex
figur
kindli
provid
melissann
de
wispelaer
spec
librari
follow
dock
consensu
rescor
result
compound
subsequ
biolog
evalu
four
exhibit
activ
chikv
best
compound
ec
cc
mechan
action
studi
indic
effect
earli
stage
viral
replic
probabl
viru
entri
thirteen
new
analogu
deriv
hit
compound
prepar
test
far
none
prove
potent
hit
synthesi
improv
analogu
modeofact
studi
ongo
marcella
bassetto
also
cardiff
univers
report
applic
sever
differ
comput
approach
identif
novel
inhibitor
zikv
replic
crystal
structur
proteas
helicas
methyltransferas
use
perform
dockingbas
virtual
screen
commerci
intern
compound
librari
among
silico
hit
one
scaffold
exhibit
antizikv
activ
cellbas
assay
parallel
seri
novel
nucleosid
analogu
design
target
flavivirusconserv
hydrophob
pocket
proxim
sam
bind
site
zikv
mtase
synthesi
evalu
new
analogu
led
identif
hit
ec
rang
toxic
cellviabl
assay
final
homolog
model
activ
complex
polymeras
built
use
evalu
potenti
bind
known
broadspectrum
nonnucleosid
inhibitor
viral
polymeras
best
silico
hit
use
start
point
shapebas
screen
commerci
small
molecul
compound
select
vitro
evalu
third
antizikv
hit
ec
rang
identifi
three
molecul
modifi
increas
potenc
chenglong
zhao
univers
hamburg
germani
describ
design
synthesi
seri
nonsymmetr
prodrug
triphosph
aim
deliv
cell
hydrolysi
studi
prepar
prodrug
phosphat
buffer
solut
pb
ph
demonstr
stabil
increas
increas
length
alkyl
chain
pb
halfliv
prodrug
around
h
tlymphocyt
cem
cell
extract
halfliv
dramat
reduc
h
h
shown
biodegrad
prodrug
moieti
cleav
one
compound
alkyl
c
h
stabl
pb
least
h
even
importantli
contrast
cem
extract
compound
also
exhibit
good
antivir
activ
tkdefici
cemtk
cell
cultur
infect
moreov
counterpart
substrat
hivrt
effici
use
human
dnapol
contrast
ttp
may
point
increas
select
nucleosid
triphosph
toward
viral
enzym
compar
cellular
polymeras
david
corti
humab
biom
bellinzona
switzerland
describ
histori
serotherapi
recent
advanc
use
monoclon
antibodi
treat
human
diseas
new
antibodi
engin
technolog
develop
target
conserv
epitop
highli
variabl
virus
improv
antibodi
effector
function
multipl
region
specif
viral
target
stem
influenza
viru
hemagglutinin
target
specif
antibodi
potenti
prophylaxi
therapi
viral
infect
david
gave
exampl
mechan
action
neutral
antibodi
direct
influenza
viru
rsv
zikv
antibodi
use
identifi
protect
antigen
design
vaccin
ron
fouchier
depart
virosci
erasmu
mc
rotterdam
netherland
describ
influenza
viru
infect
immunosuppress
patient
whose
impair
immun
may
caus
prolong
viru
infect
combin
antivir
treatment
lead
emerg
virus
resist
mutat
immunocompromis
ferret
use
model
evalu
treatment
strategi
compar
immunocompet
ferret
show
prolong
presenc
viral
rna
greater
total
amount
viru
shed
although
oseltamivir
treatment
reduc
shed
result
emerg
neuraminidas
inhibitorresist
virus
mutat
aros
immunocompromis
ferret
similar
seen
patient
xavier
saelen
vib
center
medic
biotechnolog
depart
biomed
molecular
biolog
ghent
univers
ghent
belgium
describ
treatment
option
avail
patient
infect
rsv
promis
new
smallmolecul
antivir
target
fusion
protein
polymeras
evalu
clinic
addit
number
human
monoclon
antibodi
well
singledomain
antibodi
develop
target
rsv
fusion
glycoprotein
molecul
although
primarili
intend
prophylact
use
antibodi
therapeut
effect
anim
model
polymeras
inhibitor
greater
potenc
fusion
proteintarget
antibodi
studi
evalu
smallmolecul
inhibitor
rsv
challeng
studi
human
demonstr
therapeut
benefit
long
drug
administ
earli
possibl
rsv
becam
detect
carmen
mirabelli
ku
leuven
leuven
belgium
describ
use
human
airway
epitheli
cell
bronchial
origin
huaec
studi
rsv
infect
evalu
rsv
inhibitor
rsva
replic
effici
huaec
viral
rna
shed
week
infect
treatment
fusion
inhibitor
effect
ad
time
infect
replic
inhibitor
nucleosid
nonnucleosid
elicit
mark
antivir
effect
even
treatment
delay
one
three
day
infect
brett
hurst
utah
state
univers
logan
utah
usa
describ
use
human
intraven
immunoglobulin
hivig
treatment
enteroviru
ev
infect
mous
model
respiratori
neurolog
diseas
respiratori
model
hivig
reduc
lung
viru
titer
histopatholog
evid
injuri
lung
tissu
reduc
viremia
viru
spread
cn
neurolog
model
hivig
prevent
paralysi
mortal
administ
within
h
infect
work
provid
evid
use
hivig
treatment
respiratori
infect
prevent
system
viral
spread
meehyein
kim
viru
research
group
korea
research
institut
chemic
technolog
daejeon
republ
korea
describ
use
retino
acidinduc
gene
rigi
agonist
treatment
influenza
viru
infect
kim
gave
exampl
synthet
rna
modifi
enhanc
efficaci
use
rigi
agonist
immunotherapi
transfect
optim
rigi
agonist
rna
suppress
influenza
viru
protein
express
intranas
immun
mice
inactiv
influenza
viru
vaccin
along
agonist
adjuv
afford
complet
protect
mouseadapt
infect
mice
given
vaccin
alon
surviv
challeng
lisa
evan
dewald
emerg
biosolut
gaithersburg
md
usa
describ
use
iminosugar
hosttarget
glucomimet
inhibit
glycosyl
viral
envelop
glycoprotein
oral
treatment
protect
mice
lethal
infect
mouseadapt
oseltamivirsensit
oseltamivirresist
influenza
b
virus
examin
abil
influenza
viru
develop
resist
viru
passag
mice
presenc
absenc
drug
viru
isol
lung
identifi
chang
genom
nonsynonym
mutat
identifi
five
passag
absenc
appar
viral
escap
mutant
follow
sustain
exposur
emerg
infect
ebola
treatment
work
dark
spotlight
michael
jacob
royal
free
hospit
london
uk
west
african
ebola
epidem
led
team
treat
patient
royal
free
hospit
london
includ
case
encephalomyelit
infect
nurs
earlier
recov
ebola
viru
diseas
michael
jacob
note
spite
epidem
last
nearli
three
year
estim
case
consider
experi
administ
experiment
treatment
patient
africa
usa
europ
still
therapi
proven
efficaci
part
difficulti
disagr
among
expert
experiment
medic
ethic
administ
trial
design
provid
evid
efficaci
mike
therefor
devot
part
lectur
current
effort
world
health
organ
facilit
use
promis
treatment
futur
infecti
diseas
outbreak
mean
new
ethic
framework
monitor
emerg
use
unregist
intervent
meuri
intend
appli
proven
effect
treatment
diseas
high
mortal
clinic
studi
start
immedi
data
avail
provid
preliminari
support
efficaci
safeti
use
support
scientif
committe
basi
favor
riskbenefit
analysi
novel
therapi
introduc
countri
author
ethic
committe
must
approv
use
adequ
resourc
must
avail
minim
risk
patient
must
give
inform
consent
use
drug
must
monitor
data
share
time
manner
mike
note
although
meuri
framework
provid
safeguard
patient
includ
reliabl
mean
evalu
drug
efficaci
consid
best
obtain
random
trial
although
preagre
trial
design
remaind
lectur
mike
review
cours
ill
ebola
patient
treat
royal
free
hospit
refer
therapi
might
employ
current
outbreak
democrat
republ
congo
comment
although
individu
clinic
histori
provid
evid
efficaci
patient
data
may
suggest
benefit
present
promis
therapi
appear
zmapp
mapp
biopharmaceut
inc
data
also
support
use
nucleotid
analogu
prodrug
remdesivir
gilead
scienc
meuri
framework
also
suggest
tripl
human
monoclon
antibodi
mab
combin
regeneron
pharmaceut
could
use
zmapp
remdesivir
avail
express
uncertainti
efficaci
dose
favipiravir
note
might
use
drug
list
avail
second
plenari
lectur
session
rolf
hilgenfeld
describ
activ
alphaketoamid
broadspectrum
inhibitor
coronaviru
enteroviru
replic
main
proteas
coronavirus
proteas
enterovirus
share
similar
activesit
architectur
uniqu
requir
glutamin
posit
substrat
rolf
group
perform
structurebas
design
peptidomimet
alphaketoamid
inhibitor
main
proteas
close
inspect
crystal
structur
earli
lead
compound
complex
target
proteas
reveal
differ
pocket
small
cover
lid
enzym
larg
cover
sarscov
mpro
larg
cover
sarscov
mpro
also
featur
high
plastic
site
best
nearequipot
inhibitor
cyclopentylmethyl
cyclohexylmethyl
display
lowor
ec
valu
enterovirus
alphaand
betacoronavirus
cell
compound
exhibit
highest
activ
antivir
describ
merscov
preclin
develop
namjoon
cho
nanyang
technolog
univers
singapor
describ
activ
synthet
peptid
inhibit
replic
zikv
mosquitoborn
virus
capabl
enter
central
nervou
system
peptid
select
target
highcurvatur
phospholipid
membran
enclos
suscept
virus
composit
engin
high
vivo
stabil
mous
model
zikv
infect
treatment
start
three
day
viru
challeng
protect
mortal
markedli
reduc
clinic
symptom
addit
system
effect
peptid
cross
bloodbrain
barrier
bbb
reduc
viral
load
brain
protect
zikvinduc
bbb
injuri
find
support
potenti
brainpenetr
peptid
treat
neurotrop
viral
infect
kristina
kovacikova
leiden
univers
medic
center
netherland
describ
identif
inhibitor
chikv
use
revers
genet
method
identifi
protein
target
screen
selenonucleosid
carbocycl
nucleosid
analogu
yield
potent
compound
ec
select
index
select
resist
mutant
identifi
two
mutat
respons
resist
compound
base
result
biochem
assay
purifi
alphaviru
kristina
colleagu
hypothes
directli
affect
alphaviru
methyltransferas
activ
addit
indirect
effect
viral
replic
inhibit
cellular
sadenosyllhomocystein
hydrolas
eyer
veterinari
research
institut
brno
czech
republ
report
tickborn
enceph
viru
strongli
inhibit
modifi
nucleosid
iminocnucleosid
biocryst
pharmaceut
escap
mutant
emerg
rel
quickli
passag
presenc
drug
viru
resist
nucleosid
mutat
activ
site
rna
polymeras
show
small
plaqu
mark
decreas
replic
fit
vitro
loss
neuroinvas
mice
contrast
viru
resist
differ
mutat
show
chang
plaqu
size
vitro
growth
kinet
neuroinvas
also
strikingli
decreas
structur
studi
molecular
dock
identifi
molecular
basi
resist
mutant
virus
anna
heidelberg
univers
germani
note
nonstructur
protein
protein
denv
known
essenti
replic
molecular
mechan
remain
elus
scatturo
colleagu
previous
report
panel
mutant
abrog
denv
replic
scaturro
et
al
character
reveal
novel
interact
precursor
polyprotein
identifi
residu
critic
determin
alanin
substitut
abrog
precursor
protein
bind
abolish
rna
replic
affect
secret
electron
microscopybas
studi
suggest
interact
precursor
necessari
format
membran
replic
organel
interfac
precursor
may
promis
target
antivir
therapi
jinhong
chang
blumberg
institut
doylestown
pa
usa
describ
effort
determin
mechan
action
benzodiazepin
compound
bdaa
inhibit
replic
yellow
fever
viru
yfv
vitro
hamster
guo
et
al
examin
bdaaresist
yfv
found
compound
interact
threeresidu
motif
center
protein
addit
direct
inhibit
viral
replic
rnaseq
analysi
reveal
bdaa
treatment
also
significantli
enhanc
level
mrna
specifi
broad
rang
cytokin
chemokin
isg
use
knockout
technolog
jinhong
colleagu
demonstr
mav
adaptor
rna
sensor
rigi
essenti
enhanc
yfvinduc
cytokin
respons
inhibit
yfv
replic
find
suggest
bdaa
impair
rna
replic
physic
disrupt
replic
complex
caus
releas
viral
rna
activ
rigi
andor
stimul
antivir
respons
may
wang
harvard
medic
school
boston
usa
describ
activ
novel
small
molecul
current
design
lassa
fever
viru
lfv
attach
cell
surfac
lfv
virion
endocytos
transport
late
endosomelysosom
acidif
promot
bind
viral
glycoprotein
put
receptor
cholesterolbind
integr
membran
protein
may
colleagu
found
compet
cholesterol
bind
membran
distal
domain
cholesterol
strongli
enhanc
interact
viral
gp
block
therefor
propos
bind
lfv
gp
depend
presenc
cholesterol
domain
displac
prevent
viru
entri
merel
oeyen
rega
institut
ku
leuven
present
data
activ
denv
zikv
novel
peptid
labyrinthopeptin
previous
shown
inhibit
hiv
herp
simplex
viru
hsv
ferir
et
al
antiflavivir
activ
independ
viral
serotypestrain
test
host
cell
line
flavivirussuscept
vero
raji
dcsign
cell
ec
rang
liver
cell
line
ic
denv
astrogli
placent
cell
line
ic
zikv
antivir
activ
also
confirm
monocytederiv
dendrit
cell
infect
differ
denv
serotyp
use
flow
cytometri
qpcr
mechan
action
studi
suggest
interfer
interact
viral
envelop
cellular
receptor
play
role
viral
entri
justin
juland
utah
state
univers
logan
ut
usa
describ
evalu
human
bispecif
neutral
antibodi
wang
et
al
mous
model
zikv
diseas
human
mab
bind
epitop
diii
e
protein
potent
neutral
multipl
zikv
strain
escap
mutant
emerg
vitro
vivo
bind
specif
second
mab
target
dii
combin
bispecif
antibodi
escap
mutant
seen
prophylact
efficaci
evalu
model
congenit
zikv
infect
mice
congenit
expos
pup
smaller
normal
reduc
head
length
often
show
hear
loss
dam
infect
day
pregnanc
administ
h
viru
challeng
signific
improv
dam
surviv
reduct
viral
rna
placenta
fetu
matern
spleen
brain
sampl
trend
toward
increas
pup
size
placent
weight
data
suggest
earlier
treatment
effect
adult
male
mice
infect
zikv
treat
show
reduc
viru
level
test
indic
antibodi
reach
immuneprivileg
site
treatment
might
prevent
sexual
transmiss
kristina
lanko
rega
institut
ku
leuven
describ
develop
new
vitro
assay
develop
directact
antivir
human
parechovirus
hpev
caus
sepsislik
ill
lifethreaten
neurolog
complic
infant
find
virus
replic
well
african
green
monkey
kidney
cell
line
bgm
colleagu
analyz
kinet
replic
cell
intracellular
viral
rna
level
peak
h
postinfect
h
day
postinfect
extracellular
genom
copi
number
virus
compar
determin
certain
compound
inhibit
enteropicornaviru
replic
also
inhibit
replic
favipiravir
nucleosid
analogu
activ
effect
ec
enterovirusspecif
inhibitor
pleconaril
rupintrivir
inhibit
hpev
randal
lanier
chimerix
durham
nc
usa
gave
note
first
public
present
data
antinoroviru
activ
novel
purin
nucleosid
analogu
origin
identifi
screen
compound
librari
mousederiv
viru
compound
appear
target
activ
site
rnadepend
rna
polymeras
highli
conserv
among
human
mous
norovirus
therefor
activ
viral
genotyp
ec
valu
rang
panel
divers
calicivirus
transform
cell
line
replicon
mice
oral
administ
show
dosedepend
inhibit
viru
replic
gastrointestin
tissu
label
drug
local
gut
compound
effect
human
noroviru
hunov
human
mucos
stem
cellderiv
organoid
suggest
broadli
effect
divers
human
norovirus
complet
preclin
studi
includ
anim
toxicolog
rate
format
halflif
activ
triphosph
relev
cell
type
resist
passag
enterocyt
transport
identif
vivo
distribut
studi
progress
phase
clinic
develop
valeria
cagno
univers
geneva
began
present
note
ideal
strategi
fight
viral
infect
develop
broadspectrum
treatment
irrevers
inhibit
infect
describ
synthesi
sulfon
aciddecor
gold
nanoparticl
mimic
cellular
attach
receptor
heparan
sulfat
proteoglycan
wide
use
virus
virus
bind
materi
undergo
structur
deform
irrevers
loss
infect
shown
electron
microscopi
molecular
dynam
simul
nanomolar
concentr
irrevers
inactiv
hsv
human
papilloma
viru
rsv
denv
zikv
vitro
without
measur
cytotox
also
activ
ex
vivo
human
cervicovagin
histocultur
vivo
rsvinfect
mice
nanoparticl
gold
replac
biocompat
sugar
core
show
similar
efficaci
similar
strategi
use
target
virus
depend
sialic
acid
receptor
brian
gentri
drake
univers
de
moin
iowa
usa
discuss
metabol
activ
monohydroxymethyl
methylenecyclopropan
mcpn
nucleosid
analogu
moieti
mcpn
ether
thioether
substitu
known
broadspectrum
antiherpesviru
agent
komazinmeredith
et
al
synguanol
cyclopropavir
consid
respect
firstand
secondgener
mcpn
propos
mechan
action
involv
sequenti
phosphoryl
triphosph
tp
form
inhibit
viral
dna
polymeras
thirdgener
mcpn
potent
broader
spectrum
antivir
activ
compar
first
second
gener
increas
potenc
herpesvirus
relat
observ
increas
cytotox
mechan
action
similar
gcv
two
addit
distinct
step
gcv
convert
monophosph
mp
form
cmvencod
protein
kinas
follow
endogen
cellular
phosphoryl
activ
gcvtp
inhibit
viral
dna
synthesi
contrast
previous
shown
partial
phosphoryl
cellular
kinas
allow
overcom
resist
second
butyleth
moieti
guanin
ring
must
enzymat
remov
character
step
pentostatin
inhibitor
adenosin
deaminas
ada
coincub
result
reduct
ec
vs
moieti
guanin
ring
enzymat
remov
ada
suggest
remov
follow
phosphoryl
drug
mp
remark
incub
cellular
extract
construct
convers
synguanolmp
demonstr
futur
research
focu
convers
synguanolmp
presenc
absenc
dcf
potent
adenosin
deaminas
inhibitor
convers
triphosph
infect
cell
liang
sun
rega
institut
ku
leuven
describ
inhibitor
enteroviru
major
etiolog
agent
hand
foot
mouth
diseas
caus
sever
neurolog
complic
young
children
colleagu
report
earlier
novel
class
hiv
inhibitor
tryptophan
dendrim
also
block
replic
lownmhighpm
rang
martinezgualda
et
al
resist
select
revers
genet
cryoem
show
singl
molecul
prototyp
dendrim
bind
vertex
viral
capsid
receptor
pulldown
found
dendrim
inhibit
viral
attach
host
cell
block
interact
least
two
viral
coreceptor
pselectin
glycoprotein
glycosaminoglycan
heparan
sulfat
suggest
carboxyl
group
compet
receptor
bind
positivelycharg
cluster
vertex
bart
tarbet
utah
state
univers
logan
ut
usa
describ
activ
novel
hosttarget
antivir
inhibitor
model
enteroviru
infect
mice
although
intranas
challeng
mice
caus
mortal
weight
loss
decreas
lung
function
observ
plethysmographi
elev
lung
viru
titer
proinflammatori
cytokin
follow
treatment
modest
antivir
effect
observ
mice
given
mgkg
show
signific
decreas
lung
titer
neurolog
model
infect
mice
treatment
prevent
weight
loss
neurolog
sign
mortal
howev
neurolog
model
mice
treat
mgkg
protect
infect
result
demonstr
util
mous
model
evalu
antivir
effect
potenti
therapi
infect
julio
villalvazo
guerrero
institut
virolog
hannov
medic
school
germani
start
present
note
worldwid
billion
peopl
year
age
infect
repres
popul
africa
america
hsv
associ
signific
diseas
particularli
immunocompromis
patient
includ
lifethreaten
infect
newborn
longterm
disabl
enceph
eye
infect
novel
compound
target
viru
assembl
could
complement
exist
antihsv
drug
order
reduc
risk
emerg
drugresist
viral
mutant
report
strain
hsv
express
gfp
employ
phenotyp
screen
compound
hit
compound
inhibit
hsv
plaqu
format
vero
hela
human
immort
keratinocyt
hacat
cell
line
ec
rang
cytotox
concentr
cc
rang
compound
show
higher
select
indic
acyclovir
gold
standard
therapi
hsv
experi
use
dualcolor
hsv
strain
express
gfp
tegument
red
cherri
capsid
ivanova
et
al
perform
identifi
step
viral
replic
cycl
hinder
compound
inhibit
nuclear
capsid
format
capsid
egress
cytoplasm
three
reduc
number
capsid
cytoplasm
block
bind
ctermin
domain
larg
essenti
tegument
protein
nuclear
cytoplasm
capsid
timeofaddit
studi
show
compound
still
activ
ad
h
infect
work
ongo
elucid
inhibitori
potenti
varicella
zoster
viru
cmv
kaposi
sarcoma
hv
determin
molecular
andor
host
target
dana
wolf
hadassah
hospit
hebrew
univers
faculti
medicin
jerusalem
israel
report
artemison
novel
potent
inhibitor
cmv
antimalari
artemisinin
deriv
artesun
shown
inhibit
cmv
vitro
via
inhibit
cmvinduc
activ
pathway
virusmodul
cell
cycl
progress
state
support
effici
hcmv
replic
shapira
et
al
inconsist
result
obtain
clinic
artesun
treatment
cmv
diseas
develop
novel
artemisinin
deriv
enhanc
antivir
activ
envisag
artemison
emerg
potent
inhibitor
cmv
includ
laboratoryadapt
strain
lowpassag
clinic
isol
artemison
demonstr
superior
activ
epitheli
cell
fibroblast
artesun
inhibit
hcmv
plaqu
format
ec
valu
compar
ganciclovir
timeofaddit
studi
show
drug
inhibit
earli
stage
cmv
replic
cycl
affect
transcript
immediatelyearli
ie
gene
effect
depend
multipl
infect
moi
howev
inhibit
late
stage
replic
cycl
found
independ
moi
suggest
novel
mechan
action
artemison
inhibitori
activ
specif
hcmv
close
relat
rhesu
macaqu
cmv
consist
activ
murin
cmv
importantli
artemison
effect
hamper
cmv
infect
determin
quantif
viral
antigen
fluoresc
microscopi
viral
mrna
clinic
relev
multicellular
model
integr
human
placent
tissu
maintain
organ
cultur
model
close
recapitul
authent
viral
infect
mirror
natur
divers
cmvinfect
target
cell
characterist
celltocel
mode
viral
spread
observ
vivo
oikninedjian
et
al
base
promis
find
potenti
clinic
use
artemison
new
cmv
inhibitor
highlight
transcript
profil
hiv
latenc
angela
ciuffi
institut
microbiolog
lausann
univers
hospit
univers
lausann
lausann
switzerland
angela
ciuffi
began
lectur
note
despit
great
effort
devot
identif
latencyrevers
agent
lra
aim
purg
hiv
latent
reservoir
small
fraction
latent
infect
cell
effect
stimul
lra
due
heterogen
natur
hivinfect
cell
character
transcript
heterogen
team
perform
singlecel
rna
sequenc
scrnaseq
use
fluidigm
technolog
primari
model
hiv
latenc
analyz
transcript
profil
latent
infect
singl
cell
divid
three
group
untreat
histon
deacetylas
inhibitor
vorinostat
saha
treat
tcrstimul
cell
princip
compon
analysi
identifi
two
differ
cluster
three
group
correl
differ
hiv
express
deep
stage
tcell
cluster
poorli
respons
extern
stimuli
difficult
reactiv
induc
stage
tcell
cluster
easier
stimul
reactiv
also
found
specif
cellular
signatur
associ
success
hiv
reactiv
vivo
analysi
singl
cell
hivinfect
individu
confirm
exist
two
cellular
popul
might
reflect
two
distinct
rest
cellular
state
display
differ
potenti
cell
stimul
hiv
reactiv
identif
capsidbind
protein
recogn
nuclear
hiv
capsid
promot
cgasmedi
innat
immun
activ
dendrit
cell
nicola
manel
institut
curi
psl
research
univers
pari
franc
first
part
lectur
nicola
manel
gave
overview
role
dna
sensor
cyclic
gmpamp
synthas
cga
induct
innat
immun
respons
vpx
infect
human
monocytederiv
dendrit
cell
dc
thank
vpx
infect
dc
high
level
activ
innat
immun
sens
dna
cgascgampst
protein
lahay
et
al
manel
team
abl
packag
cgamp
viral
particl
vlp
transmit
target
cell
induc
immun
respons
highlight
implic
cancer
immunotherapi
sinc
cgampvlp
induc
antitumor
cell
respons
vaccin
cgampvlp
could
deliv
along
antigen
intramuscular
inject
therebi
exert
immunomodulatori
role
second
part
lectur
focus
depict
regulatori
pathway
control
sens
cgasst
identif
previous
unreport
capsidbind
protein
bind
directli
hiv
capsid
affin
repres
import
contribut
field
manel
colleagu
demonstr
differ
approach
exist
nuclear
protein
directli
bind
hiv
capsid
requir
interferon
induct
respons
dc
also
show
associ
protein
cga
essenti
presenc
cga
nucleu
infect
cell
strategi
hiv
cure
earli
lesson
shock
kill
trial
ole
schmeltz
dept
infecti
diseas
aarhu
univers
hospit
aarhu
denmark
ole
review
import
result
obtain
hiv
shock
kill
trial
begin
present
conceiv
strategi
cure
hiv
infect
mean
shortterm
administr
latencyrevers
agent
lra
increas
transcript
protein
express
plasma
rna
induc
viru
reactiv
mani
pathway
may
target
lra
vorinostat
provid
first
direct
measur
disrupt
latenc
vivo
mean
induct
unsplic
cellassoci
hivrna
accompani
rebound
viral
particl
plasma
archin
et
al
subsequ
use
lra
panobinostat
induc
extracellular
rna
product
plasma
confirm
possibl
induc
vivo
reactiv
howev
ole
highlight
none
earli
trial
even
use
potent
lra
romidepsin
abl
reduc
size
latent
reservoir
art
interrupt
viral
rebound
therefor
conclud
shock
exist
kill
last
part
lectur
review
newer
studi
combin
lra
therapeut
vaccin
aim
improv
kill
reactiv
cell
studi
test
lra
agonist
may
also
enhanc
antivir
immun
antivir
consortium
mari
european
train
network
wwwantiviralsetneu
train
phd
student
earli
stage
research
esr
sinc
start
coordin
frank
van
kuppeveld
utrecht
univers
netherland
introduc
network
highlight
special
train
element
particular
close
collabor
academ
industri
partner
shown
type
partner
employ
train
esr
also
mention
broad
spectrum
cours
scientif
complementari
skill
network
offer
esr
young
research
learn
year
train
exemplifi
rest
session
gave
present
describ
project
draw
attent
audienc
present
icar
esr
held
oral
present
main
program
remain
present
poster
exampl
achiev
esr
given
two
oral
present
lisa
bauer
utrecht
univers
show
new
interdisciplinari
research
project
initi
five
phd
student
four
differ
institut
focus
mode
action
fluoxetin
inhibitor
enteroviru
atpas
studi
brought
togeth
disciplin
structurebas
drug
design
medicin
chemistri
cardiff
univers
univers
vienna
structur
biolog
aixmarseil
univers
molecular
virolog
utrecht
univers
creat
basi
develop
new
molecul
base
senantiom
fluoxetin
hope
without
sideeffect
antidepress
angelica
corcuera
present
result
phd
research
perform
one
antivir
industri
partner
aicuri
studi
mechan
action
variou
hbv
capsid
binder
use
combin
sizeexclus
chromatographi
electron
microscopi
fluoresc
microscopi
convincingli
demonstr
mechan
action
three
new
capsidassembl
modifi
similar
sulfamoylbenzamid
phenylpropenamid
distinct
heteroarylpyrimidin
hap
